Barclays raised the firm’s price target on Karyopharm (KPTI) to $10 from $5 and keeps an Overweight rating on the shares. The company’s Q1 selinexor revenue of $21.1M was below consensus of $28.7M, but the key focus for investors is on pivotal myelofibrosis data in late 2025/early 2026, the analyst tells investors in a research note. The firm adjusted its model to account for the recent stock split.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KPTI:
- Karyopharm Therapeutics Reports Q1 2025 Earnings and Clinical Progress
- Karyopharm reports Q1 EPS ($2.77), consensus ($3.09)
- Karyopharm sees 2025 revenue $140M-$155M, consensus $149.62M
- KPTI Earnings this Week: How Will it Perform?
- Biotech stocks slide as Marks resignation seen being negative for sector